May 17, 2020

Funding given nanotechnology study

nanotechnolgy
Nottingham University
innovative healthcare
Admin
2 min
Nanotechnology could provide breakthroughs
Follow @ WDMStanJackson Scientists at Nottingham are engineering plastic implants to help in the treatment of a variety of injuries. Scientists at the...

Scientists at Nottingham are engineering plastic implants to help in the treatment of a variety of injuries.

Scientists at the Russell Group University will be using funding from the EPSRC worth £1.2 million, to pioneer research into new ways of manufacturing and producing nanoparticles and nanocomposites to be used for drug delivery and bone tissue regeneration. 

“We will be combining hydroxyapatite nanoplatelets with resorbable plastics to create implant materials that will be able to fix things such as fractures”, said Andrew Parsons from Nottingham University’s faculty of engineering.   Nanocomposites enable significant improvements in mechanical properties over other materials that are currently standard in certain areas of healthcare.

“Nanocomposites are well suited to use in this way as the bones of the body are already natural hydroxyapatite nanocomposites”, continued Parsons.

 

 

The implants are plastic and will therefore be much lighter and far more flexible than current solutions.  They will also generate less interference with X-Ray or MRI imaging, as well as airport scanners. 

The team at Nottingham University are working in conjunction with a number of companies who will provide support both in a consultancy sense and also in ensuring that the right equipment is available to the team.  The challenge for the scientists is to move the research from the lab stage, where the structures are currently being tested, into clinical trial stage and then to large scale manufacture. 

Share article

Jun 23, 2021

Introducing Dosis - the AI powered dosing platform

AI
medication
personalisedmedicine
chronicdisease
3 min
Dosis is an AI-powered personalised medication dosing platform that's on a mission to transform chronic disease management

Cloud-based platform Dosis uses AI to help patients and clinicians tailor their medication plans. Shivrat Chhabra, CEO and co-founder, tells us how it works. 

When and why was Dosis founded?
Divya, my co-founder and I founded Dosis in 2017 with the purpose of creating a personalised dosing platform. We see personalisation in so many aspects of our lives, but not in the amount of medication we receive. We came across some research at the University of Louisville that personalised the dosing of a class of drugs called ESAs that are used to treat chronic anaemia. We thought, if commercialised, this could greatly benefit the healthcare industry by introducing precision medicine to drug dosing. 

The research also showed that by taking this personalised approach, less drugs were needed to achieve the same or better outcomes. That meant that patients were exposed to less medication, so there was a lower likelihood of side effects. It also meant that the cost of care was reduced. 

What is the Strategic Anemia Advisor? 
Dosis’s flagship product, Strategic Anemia Advisor (SAA), personalises the dosing of Erythropoiesis Stimulating Agents (ESAs). ESAs are a class of drugs used to treat chronic anaemia, a common complication of chronic kidney disease. 

SAA takes into account a patient’s previous ESA doses and lab levels, determines the patient’s unique response to the drug and outputs an ESA dose recommendation to keep the patient within a specified therapeutic target range. Healthcare providers use SAA as a clinical decision support tool. 

What else is Dosis working on? 
In the near term, we are working on releasing a personalised dosing module for IV iron, another drug that’s used in tandem with ESAs to treat chronic anaemia. We’re also working on personalising the dosing for the three drugs used to treat Mineral Bone Disorder. We’re very excited to expand our platform to these new drugs. 

What are Dosis' strategic goals for the next 2-3 years? 
We strongly believe that personalised dosing will be the standard of care within the next decade, and we’re honored to be a part of making that future a reality. In the next few years, we see Dosis entering partnerships with other companies that operate within value-based care environments, where tools like ours that help reduce cost while maintaining or improving outcomes are extremely useful.

What do you think AI's greatest benefits to healthcare are?
If designed well, AI in healthcare allows for a practical and usable way to deploy solutions that would not be feasible otherwise. For example, it’s possible for someone to manually solve the mathematical equations necessary to personalise drug dosing, but it is just not practical. AI in healthcare offers an exciting path forward for implementing solutions that for so long have appeared impractical or impossible.

Share article